Amyloid-beta is the peptide that forms plaques in Alzheimer's brains. At low concentrations, it causes minimal damage. Fibrinogen is a blood protein involved in clotting. At physiological levels, it is harmless. Neither protein, studied individually at the concentrations found in early disease, produces the hallmark pathology of Alzheimer's.
Together, they do.
When amyloid-beta binds fibrinogen, the resulting complex damages both pre- and post-synaptic terminals, triggers neuroinflammation, and disrupts the blood-brain barrier — allowing blood proteins to leak into brain tissue, compounding the damage. Blocking the binding site with antibodies (including lecanemab, an FDA-approved therapy) eliminates the harmful effects. The complex is the pathogen. The individual proteins are not.
The structural implication: decades of Alzheimer's research focused on amyloid-beta as the culprit. The amyloid hypothesis drove drug development, clinical trials, and diagnostic criteria. But amyloid-beta alone, at the concentrations that matter early in disease, is insufficient. The relevant entity is the interaction — a molecular species that exists only when two harmless proteins meet.
Single-variable studies could not have found this. Measuring amyloid-beta toxicity in isolation measures the wrong thing. Measuring fibrinogen behavior in isolation measures the wrong thing. The pathological mechanism lives in the space between them — a region that neither field (amyloid biology, coagulation biology) was equipped to explore, because each studied its own component.
The disease was hiding in the interaction, not the interactors. The damage was emergent, invisible to any lens that examined one molecule at a time.